Celo Core Co. has introduced buy, a marketplace enabling AI agents to purchase computing, data, and API services directly using stablecoins like USDC, USD₮, or USA₮ on the Celo network. This removes traditional barriers such as account creation and subscriptions, allowing instant payments and seamless transactions. The platform integrates identity verification to ensure real humans back AI requests, unlocking access to premium services like Google Cloud's largest machines. This innovation supports Celo's growing ecosystem of over 450,000 daily users and aims to empower AI agents to act autonomously in digital service markets.
The Celo Core Co. launch of buy marketplace for AI agent payments is presented here with Pluang's cryptocurrency market data as context. As of Oct 13, 2026 21:51 WIB, out of 50 major cryptocurrencies priced on Pluang, 15 rose and 34 fell. Notable movers include CRV at Rp6.117 with a 1-day change of -5.62%, XTZ at Rp6.037 with +5.12%, and THETA at Rp3.688 with -4.97%.
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
Citigroup reported Q3 2026 earnings that exceeded analyst expectations, with EPS of $2.85 beating the $2.65 estimate and revenue of $23.8 billion slightly above forecasts. The bank's profit rose 40%, driven by exceptional fixed-income trading, invest...
State Street is set to report its Q3 2026 earnings with forecasts showing a 31.3% increase in earnings and 14% revenue growth, driven by strong net interest income and service fees. Despite record assets under management, higher operating and technol...
Restaurant Technologies, Inc. (RTI) released its 2026 Impact Report highlighting significant progress in sustainability and operational efficiency. In 2025, RTI recycled 393 million pounds of used cooking oil and delivered 719.4 million pounds of fre...
Over 60 companies are actively developing more than 65 medical marijuana therapies targeting conditions like chronic pain, neurological disorders, and cancer symptoms. Key drugs such as ZYN-002 and CardiolRx are in late-stage trials, with others in e...
